Industrial fermentation routes are commonly ranked from laboratory performance, yet scale-up changes the physical environment, the temporal exposure history of cells, and the economic consequences of upstream choices. This article develops an original, evidence-bounded bioprocess decision model for assessing when a route that appears superior at small scale may become less attractive after scale-dependent biological, engineering, and recovery constraints are considered. The analysis separates absolute performance loss from relative route reversal and integrates oxygen transfer, precursor and flux availability, morphology where biologically relevant, product or intermediate toxicity, robustness, and downstream recovery economics. The central proposed contribution is a comparative decision architecture in which each candidate route is assessed for scale-sensitive vulnerabilities, feasible mitigation, cross-domain interactions, and the possibility that one route incurs a larger scale penalty than another. The model does not assign universal weights or thresholds; instead, it identifies evidence states and discriminating experiments capable of changing route choice before major process commitment. Particular emphasis is placed on interactions, because oxygen limitation may alter precursor use, hydrodynamics may change morphology, toxicity may increase the value of in situ removal, and downstream burden may shift the economically preferred operating state. The framework is intended for structured precommitment reasoning rather than prospective prediction. Its principal limitations are the scarcity of matched head-to-head route comparisons across scales, imperfect fidelity of scale-down systems, model dependence in reactor simulations, host- and product-specific biology, and uncertainty in technoeconomic assumptions.
